Las Vegas, NV -- (SBWIRE) -- 10/05/2013 -- PennyStockEarnings team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks. Our Today’s Focus is On: Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX), XOMA Corp (NASDAQ:XOMA), Thermo Fisher Scientific Inc.(NYSE:TMO), Cell Therapeutics Inc (NASDAQ:CTIC)
Vertex Pharmaceuticals Incorporated (NASDAQ:VRTX) managed to keep its gain at 0.06% on below-normal volume of 1.32M shares. The stock settled at $77.21 after floating in a range of $76.60 to $77.84. Its latest price has reached market capitalization of $17.98B. Its 52-week range has been $38.44 to $89.96. Vertex Pharmaceuticals Incorporated (Vertex) is in the business of discovering, developing, manufacturing and commercializing small molecule drugs for the treatment of serious diseases.
Is VRTX Ready To Move Up? Find Out Here
XOMA Corp (NASDAQ:XOMA) traded on a volume of 1.30M Shares, higher than its standard daily volume. Shares have closed at $5.39. Over the last twelve months, the stock has gained 368.7% and faced a worst price of $2.37. XOMA Corporation (XOMA) is engaged in the discovery and development of antibody-based therapeutics. The Company’s lead drug candidate is gevokizumab (formerly XOMA 052).
Is XOMA a Solid Investment at These Levels? Read This Report for Details
Thermo Fisher Scientific Inc.(NYSE:TMO) settled up at $92.36 on below-normal volume of 1.28M shares during the last trading day. The stock has its 12-month high at $94.74 and 52-week low price was $57.21. It traded in a range of $91.33 to $92.88 during the last trading day. Thermo Fisher Scientific Inc. (Thermo Fisher) is engaged in serving science. It operates in three segments: Analytical Technologies, Specialty Diagnostics and Laboratory Products and Services.
Is TMO a Solid Investment at These Levels? Just Go Here and Find Out
In the last trading session, Cell Therapeutics Inc (NASDAQ:CTIC) was on low volume, trading at a volume of 1.27M versus its average daily volume of 2.46M shares. At $1.59, the stock has attained market capitalization of 182.49M. Cell Therapeutics, Inc. (CTI) is a biopharmaceutical company focused on the acquisition, development, and commercialization of less toxic ways to treats cancer.
Will Investors Buy CTIC After Reading This News? Just Go Here and Find Out
PennyStockEarnings.com is keen to discover penny stocks with the potential to make short and long-term gains.
PSE Team record for picking gainers is one of the best in the business, and our followers continue to make substantial profits – even in bear markets. Our Team includes top analysts and use level II screeners to get you the information you need to make intelligent decisions for trading penny stocks.
PLEASE NOTE WELL: The employees of PennyStockEarnings.com are not registered as Investment Advisors in any jurisdiction whatsoever. Never invest in any stock featured on our site or emails unless you can afford to lose your entire investment. Investing in “penny stocks” is highly speculative.
Verify all claims and do your own due diligence on all securities. PennyStockEarnings.com profiles are not a solicitation or recommendation to buy, sell or hold securities. PennyStockEarnings.com is not offering securities for sale. Neither PennyStockEarnings.com nor its owners, operators, affiliates or anyone disseminating information on its behalf is registered as an Investment Advisor under any federal or state law and none of the information provided by PennyStockEarnings.com, its owners, operators, affiliates or anyone disseminating information on its behalf should be construed as investment advice or investment recommendations. PennyStockEarnings.com does not recommend that the securities profiled should be purchased, sold or held.
Read Full Disclaimer Here: http://www.pennystockearnings.com/disclaimer/
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)